Dermorphin dosage protocol

What the compound is

Dermorphin is a heptapeptide, meaning it is a peptide composed of seven amino acids. It was isolated from the skin of Amazonian frogs (PMID 30538538, PMID 9949868). This peptide is notable for containing a D-amino acid in its sequence (PMID 3574608, PMID 9949868). Its full sequence is Tyr-D-Ala-Phe-Gly-Tyr-Pro-Ser-NH2 (PMID 9949868, PMID 21126548).

Traditionally, Amazonian tribes used substances containing dermorphin, referred to as "Kambo" or "Sapo," to enhance physical and psychic skills (PMID 30538538).

How it is thought to work

Dermorphin is a μ-opioid receptor-binding peptide (PMID 25376170). It acts as a selective μ-receptor agonist (PMID 3574608, PMID 21126548) and has a very high affinity and selectivity for these receptors (PMID 21126548). Binding sites for dermorphin have been observed in both central and peripheral organs in animals (PMID 3574608).

The N-terminal tetrapeptide of dermorphin is considered the minimal sequence for agonistic activity at μ-opioid receptors (PMID 21126548). Some dermorphin analogs may also stimulate the release of dynorphins through μ-opioid receptor activation (PMID 21126548).

What laboratory and animal studies report

In animal studies, dermorphin administered centrally has produced significant autonomic responses (PMID 3574608). Intracerebroventricular injection in rabbits and chicks caused analgesia, catalepsy, and changes in EEG and behavior (PMID 6178095). In rats, it sharply reduced gastric emptying time and gastric acid output, and stimulated prolactin release (PMID 6178095).

Pharmacokinetic studies in horses showed that after intravenous administration, dermorphin had distribution and elimination half-lives of approximately 0.09 hours and 0.76 hours, respectively. After intramuscular administration, the terminal elimination half-life was about 0.68 hours, with bioavailability ranging from 47-100% (PMID 25376170). In horses, dermorphin was detected in plasma for 12 hours and in urine for 48 or 72 hours following intravenous or intramuscular administration, respectively (PMID 25376170).

In pithed rats, intravenous dermorphin had no effect on basal heart rate or blood pressure, nor did it modify sympathetic stimulation-evoked pressor and tachycardic responses or the release of norepinephrine and epinephrine (PMID 3574608). In mice, a dermorphin-ranatensin hybrid peptide (LENART01) produced dose-dependent antinociceptive effects in inflammatory pain, which were reversed by naloxone (PMID 38612817). This hybrid peptide also showed less locomotor dysfunction and withdrawal syndrome compared to morphine in mice (PMID 38612817).

Human evidence so far

Dermorphin has been shown to cause both central and peripheral effects in humans following intravenous administration (PMID 25376170).

Early clinical trial results from 1985, involving a randomized, placebo-controlled study, reported that intrathecal dermorphin was superior to both placebo and morphine for postoperative pain (PMID 30538538).

Open questions and limitations

Despite early promising clinical results in humans, interest in dermorphin decreased after 1985, and it was not further introduced into clinical settings (PMID 30538538). Researchers have suggested new clinical studies to re-evaluate its safety and efficacy, particularly for intrathecal administration in postoperative pain or palliative care (PMID 30538538).

Key terms explained

μ-opioid receptor: A type of receptor in the body that opioid compounds bind to, often associated with pain relief and other effects (PMID 25376170, PMID 3574608).

Agonist: A substance that activates a receptor to produce a biological response (PMID 3574608).

Intrathecal administration: A method of administering a substance directly into the spinal canal (PMID 30538538).

Antinociception: The process of blocking the detection of a painful stimulus by sensory neurons (PMID 21126548).